Radiotherapy & Oncology
Volume 88, Issue 3 , Pages 351-358 , September 2008

Dose-individualized stereotactic body radiotherapy for T1–3N0 non-small cell lung cancer: Long-term results and efficacy of adjuvant chemotherapy

  • Yongshun Chen

      Affiliations

    • Division of Thoracic Cancer, Huaxi Hospital, Sichuan University Chengdu, China
    • ,
  • Wenhao Guo

      Affiliations

    • State Key Laboratory of Biotherapy, Huaxi Hospital, Sichuan University, Chengdu, China
    • ,
  • You Lu

      Affiliations

    • Division of Thoracic Cancer, Huaxi Hospital, Sichuan University Chengdu, China
    • State Key Laboratory of Biotherapy, Huaxi Hospital, Sichuan University, Chengdu, China
    • Corresponding Author InformationCorresponding author. You Lu, Professor of Oncology, Chief of Division of Thoracic Cancer, Cancer Center, Huaxi Hospital, West China School of Clinical Medicine Sichuan University, Guo Xue Xing 37, Chengdu 610041, China.
    • ,
  • Bingwen Zou

      Affiliations

    • Division of Thoracic Cancer, Huaxi Hospital, Sichuan University Chengdu, China

Received 30 March 2008 ,Revised 23 June 2008 ,Accepted 16 July 2008.

References 

  1. Parkin DM. Global cancer statistics in the year of 2000. Lancet Oncol. 2001;2:533–543
  2. Jemal A, Murray T, Ward E, et al. Cancer statistics 2006. CA Cancer J Clin. 2006;56:106–130
  3. Pirozynski M. 100 Years of lung cancer. Respir Med. 2006;12:2073–2084
  4. Zorn GL, Nesbitt JC. Surgical management of early stage lung cancer. Semin Surg Oncol. 2000;18:124–136
  5. Senan S, Lagerwaard FJ. The role of radiotherapy in non-small cell lung cancer. Ann Oncol. 2005;16:223–228
  6. Jassem J. The role of radiotherapy in lung cancer: where is the evidence?. Radiother Oncol. 2007;83:203–213
  7. Nyman J, Johansson KA, Hulten U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer-mature results for medically inoperable patients. Lung Cancer. 2006;51:97–103
  8. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non small cell lung cancer in patents not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax. 2001;56:28–638
  9. Verellen D, Soete G, Linthout N, et al. Optimal control of set-up margins and internal margins for intra- and extracranial radiotherapy using stereoscopic kilovoltage imaging. Cancer Radiother. 2006;10:235–244
  10. Bunn JP. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Clin Lung Cancer. 2004;6:85–98
  11. Bral S, Parijs HV, Soete G, et al. A feasibility study of image-guided hypofractionated conformal arc therapy for inoperable patients with localized non-small cell lung cancer. Radiother Oncol. 2007;84:252–256
  12. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;53:1427–1431
  13. Hof H, Herfarth K, Mu¨nter M, et al. Stereotactic single-dose radiotherapy of stage I NSCLC. Int J Radiat Oncol Biol Phys. 2003;56:335–341
  14. Whyte R, Crownover R, Murphy M, et al. Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg. 2003;75:1097–1101
  15. Rosell R, Delena M, Carpagnano F, et al. Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I–III) non small cell lung cancer (NSCLC) patients. Lung Cancer. 2005;49:S3–S4
  16. Winton T, Livingstone R, Johnson D, et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR. J Clin Oncol. 2004;22:7018
  17. Strauss G, Herndon J, Maddaus M. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of cancer and leukaemia group B (CALGB) Protocol 9633. J Clin Oncol. 2004;22:7019
  18. Xia TY, Li HQ, Sun QX, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66:117–125
  19. Chen M, James AH, Randall KT, et al. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1–3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation?. Int J Radiat Oncol Biol Phys. 2006;64:120–126
  20. Hoopers DJ, Tann M, Fletcher JW, et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer. 2007;56:229–234
  21. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101:1623–1631
  22. Nagata Y, Negoro Y, Aoki T, et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2002;52:1041–1046
  23. Senan S, Ruysscher D, Giraud P, et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol. 2004;71:139–146
  24. Jeremic B. Incidental irradiation of nodal regions at risk during limited-field radiotherapy (RT) in dose-escalation studies in nonsmall cell lung cancer (NSCLC). Enough to convert noelective into elective nodal irradiation (ENI)?. Radiother Oncol. 2004;71:123–125
  25. Chang DT, Zlotecki RA, Olivier KR. Re-examining the role of elective nodal irradiation: finding ways to maximize the therapeutic ratio. Am J Clin Oncol. 2005;28:597–602
  26. Doddoli C, Aragon A, Barlesi F, et al. Does the extent of lymph node dissection influence outcome in patients with stage I non-small cell lung cancer?. Eur J Cardiothorac Surg. 2005;27:680–685
  27. Lardinois D, Suter H, Hakki H, et al. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2005;80:268–274
  28. Suzuki K, Nagai K, Yoshida J, et al. Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer. J Thorac Cardiovasc Surg. 1999;117:593–598
  29. Withers HR, Suwinski R. Radiation dose response for subclinical metastases. Semin Radiat Oncol. 1998;8:224–228
  30. Delaney G, Barton M, Jacob S, et al. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol. 2003;4:120–128
  31. Kong FM, Randall KT, Matthew JS, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;2:324–333
  32. Saunders M, Dische S, Barret A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomized multicenter trial. CHART Steering Committee.
  33. Claude L, Pérol D, Ginestet C, et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol. 2004;71:175–181
  34. Holloway CL, Robinson D, Murray B, et al. Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer. Radiother Oncol. 2004;73:285–287
  35. Gajra A, Newman N, Gamble GP, et al. Impact of tumor size on survival in stage IA nonsmall cell lung cancer: a case for subdividing stage IA disease. Lung Cancer. 2003;42:51–57
  36. Birim O, Kappetein AP, Takkenberg JJ, et al. Survival after pathological stage IA nonsmall cell lung cancer: tumor size matters. Ann Thorac Surg. 2005;79:1137–1141
  37. Tsuchiya T, Akamine S, Muraoka M, et al. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer. 2007;56:341–348
  38. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355:479–485
  39. Tiseo M, Franciosi V, Grossi F, et al. Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice?. Eur J Cancer. 2006;42:8–16
  40. Arriagada R, Bergman B, Dunant A, et al. Cisplatin- based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med. 2004;350:351–360
  41. Hotta K, Matsuo K, Ueoka H, et al. Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol. 2004;22:3860–3867
  42. Anne MF, Sophie B, Anthony G, et al. Lung cancer in elderly patients: a retrospective analysis of practice in a single institution. Critic Rev Oncol Hematol. 2007;64:43–48

PII: S0167-8140(08)00386-1

doi: 10.1016/j.radonc.2008.07.013

Radiotherapy & Oncology
Volume 88, Issue 3 , Pages 351-358 , September 2008

Article Tools

* Image Usage & Resolution